Suchergebnisse - "Gastrointestinal Agents"

Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures.

Autoren: Wang S Passos Chaves L Olujohungbe O et al.

Quelle: Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 2057-2070. Date of Electronic Publication: 2025 Nov 26.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE

MeSH-Schlagworte: Hepatic Encephalopathy*/drug therapy , Hepatic Encephalopathy*/economics , Quality-Adjusted Life Years* , Rifaximin*/economics , Rifaximin*/therapeutic use , Gastrointestinal Agents*/economics , Gastrointestinal Agents*/therapeutic use , Rifamycins*/economics , Rifamycins*/therapeutic use, Humans ; Cost-Benefit Analysis ; Lactulose/economics ; Lactulose/therapeutic use ; United States ; Male ; Female ; Adult ; Middle Aged ; Liver Transplantation/statistics & numerical data

AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease.

Autoren: Scott FI Ananthakrishnan AN Click B et al.

Quelle: Gastroenterology [Gastroenterology] 2025 Dec; Vol. 169 (7), pp. 1397-1448.

Publikationsart: Journal Article; Practice Guideline

Info zur Zeitschrift: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 0374630 Publication Model: Print Cited Medium: Internet ISSN: 1528-0012 (Electronic) Linking ISSN: 00165085 NLM ISO Abbreviation: Gastroenterology Subsets: MEDLINE

MeSH-Schlagworte: Crohn Disease*/drug therapy , Crohn Disease*/diagnosis , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/adverse effects , Gastroenterology*/standards, Humans ; Severity of Illness Index ; Societies, Medical/standards ; Treatment Outcome ; Evidence-Based Medicine/standards ; Consensus ; Adult

Severe immune-related adverse event colitis successfully treated with single-dose infliximab in an older adult with hepatocellular carcinoma receiving STRIDE therapy.

Autoren: Tokumaru T Sakamoto S Tabuchi M et al.

Quelle: Clinical journal of gastroenterology [Clin J Gastroenterol] 2025 Dec; Vol. 18 (6), pp. 1033-1037. Date of Electronic Publication: 2025 Aug 09.

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: Springer Japan Country of Publication: Japan NLM ID: 101477246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-7265 (Electronic) Linking ISSN: 18657265 NLM ISO Abbreviation: Clin J Gastroenterol Subsets: MEDLINE

MeSH-Schlagworte: Infliximab*/administration & dosage , Infliximab*/therapeutic use , Liver Neoplasms*/drug therapy , Carcinoma, Hepatocellular*/drug therapy , Colitis*/drug therapy , Colitis*/chemically induced , Gastrointestinal Agents*/administration & dosage , Gastrointestinal Agents*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Aged, 80 and over

Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes.

Autoren: Iniesta-Navalón C Rentero-Redondo L Gómez-Espín R et al.

Quelle: Gastroenterologia y hepatologia [Gastroenterol Hepatol] 2025 Dec; Vol. 48 (10), pp. 502472. Date of Electronic Publication: 2025 May 23.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier España Country of Publication: Spain NLM ID: 8406671 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0210-5705 (Print) Linking ISSN: 02105705 NLM ISO Abbreviation: Gastroenterol Hepatol Subsets: MEDLINE

MeSH-Schlagworte: Infliximab*/blood , Infliximab*/therapeutic use , Infliximab*/pharmacokinetics , Inflammatory Bowel Diseases*/drug therapy , Inflammatory Bowel Diseases*/blood , Gastrointestinal Agents*/blood , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/pharmacokinetics, Humans ; Retrospective Studies ; Female ; Male ; Adult ; Middle Aged ; Treatment Outcome

Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysis.

Autoren: Vuyyuru SK Shaban N Yuan Y et al.

Quelle: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2025 Dec; Vol. 23 (13), pp. 2376-2398. Date of Electronic Publication: 2025 May 06.

Publikationsart: Journal Article; Systematic Review; Meta-Analysis; Review

Info zur Zeitschrift: Publisher: W.B. Saunders for the American Gastroenterological Association Country of Publication: United States NLM ID: 101160775 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-7714 (Electronic) Linking ISSN: 15423565 NLM ISO Abbreviation: Clin Gastroenterol Hepatol Subsets: MEDLINE

MeSH-Schlagworte: Colitis, Ulcerative*/drug therapy , Colitis, Ulcerative*/surgery , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/adverse effects, Humans ; Infliximab/therapeutic use ; Infliximab/adverse effects ; Colectomy/statistics & numerical data ; Randomized Controlled Trials as Topic ; Cyclosporine/therapeutic use ; Cyclosporine/adverse effects ; Acute Disease ; Treatment Outcome ; Pyrimidines/therapeutic use ; Piperidines/therapeutic use ; Immunosuppressive Agents/therapeutic use ; Adult

Cisapride for gastric emptying in diabetic patients: a meta-analysis on its efficacy and safety.

Autoren: Lu Y Xie Y Yang X et al.

Quelle: Hormones (Athens, Greece) [Hormones (Athens)] 2025 Dec; Vol. 24 (4), pp. 1131-1139. Date of Electronic Publication: 2025 Jun 26.

Publikationsart: Journal Article; Meta-Analysis; Systematic Review

Info zur Zeitschrift: Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101142469 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2520-8721 (Electronic) Linking ISSN: 11093099 NLM ISO Abbreviation: Hormones (Athens) Subsets: MEDLINE

MeSH-Schlagworte: Gastric Emptying*/drug effects , Gastroparesis*/drug therapy , Gastroparesis*/etiology , Gastroparesis*/physiopathology , Cisapride*/therapeutic use , Cisapride*/adverse effects , Cisapride*/pharmacology , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/adverse effects , Diabetes Complications*/drug therapy, Humans ; Treatment Outcome

Erythromycin plus metoclopramide combination therapy compared with erythromycin or metoclopramide monotherapy for postpyloric spiral nasoenteric tube placement: a multicenter, open-label, randomized controlled superiority trial.

Autoren: Liang S Huang J He L et al.

Quelle: The American journal of clinical nutrition [Am J Clin Nutr] 2025 Dec; Vol. 122 (6), pp. 1850-1857. Date of Electronic Publication: 2025 Sep 29.

Publikationsart: Journal Article; Multicenter Study; Randomized Controlled Trial; Comparative Study

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 0376027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-3207 (Electronic) Linking ISSN: 00029165 NLM ISO Abbreviation: Am J Clin Nutr Subsets: MEDLINE

MeSH-Schlagworte: Metoclopramide*/administration & dosage , Metoclopramide*/therapeutic use , Erythromycin*/administration & dosage , Erythromycin*/therapeutic use , Intubation, Gastrointestinal*/methods , Enteral Nutrition*/methods , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/administration & dosage, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Drug Therapy, Combination ; Critical Illness/therapy ; China ; Pylorus

PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission.

Autoren: Mathieu N Hupé M Heluwaert F et al.

Quelle: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2025 Dec; Vol. 23 (13), pp. 2597-2606. Date of Electronic Publication: 2025 May 19.

Publikationsart: Journal Article; Multicenter Study

Info zur Zeitschrift: Publisher: W.B. Saunders for the American Gastroenterological Association Country of Publication: United States NLM ID: 101160775 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-7714 (Electronic) Linking ISSN: 15423565 NLM ISO Abbreviation: Clin Gastroenterol Hepatol Subsets: MEDLINE

MeSH-Schlagworte: Infliximab*/administration & dosage , Infliximab*/adverse effects , Gastrointestinal Agents*/administration & dosage , Gastrointestinal Agents*/adverse effects , Inflammatory Bowel Diseases*/drug therapy, Humans ; Female ; Male ; Adult ; Middle Aged ; Prospective Studies ; France ; Treatment Outcome ; Administration, Intravenous ; Remission Induction ; Injections, Subcutaneous

Comparison of efficacy of rifaximin, probiotics and L-ornithine L-aspartate in overt hepatic encephalopathy: a randomized, phase IV, lactulose controlled clinical trial.

Autoren: Shahbaz A Jamil Q Iqbal SM et al.

Quelle: Trials [Trials] 2025 Nov 21; Vol. 26 (1), pp. 534. Date of Electronic Publication: 2025 Nov 21.

Publikationsart: Journal Article; Clinical Trial Protocol

Info zur Zeitschrift: Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE

MeSH-Schlagworte: Hepatic Encephalopathy*/drug therapy , Hepatic Encephalopathy*/diagnosis , Rifaximin*/therapeutic use , Rifaximin*/adverse effects , Lactulose*/therapeutic use , Lactulose*/adverse effects , Probiotics*/therapeutic use , Probiotics*/adverse effects , Dipeptides*/therapeutic use , Dipeptides*/adverse effects , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/adverse effects, Humans ; Treatment Outcome ; Randomized Controlled Trials as Topic ; Male ; Female ; Adult ; Middle Aged ; Clinical Trials, Phase IV as Topic ; Aged ; Young Adult ; Drug Therapy, Combination

Case Report: Severe kidney involvement in a case of very early onset inflammatory bowel disease.

Autoren: Drago E Carfora R Cafferata B et al.

Quelle: Frontiers in immunology [Front Immunol] 2025 Nov 19; Vol. 16, pp. 1684476. Date of Electronic Publication: 2025 Nov 19 (Print Publication: 2025).

Publikationsart: Case Reports; Journal Article

Info zur Zeitschrift: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Inflammatory Bowel Diseases*/drug therapy , Inflammatory Bowel Diseases*/complications , Inflammatory Bowel Diseases*/diagnosis , Nephritis, Interstitial*/chemically induced , Nephritis, Interstitial*/diagnosis , Nephritis, Interstitial*/drug therapy , Gastrointestinal Agents*/adverse effects , Gastrointestinal Agents*/therapeutic use , Colitis, Ulcerative*/drug therapy , Kidney*/pathology, Humans ; Female ; Child

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy.

Autoren: Caldera F Mogallapalli H Abusalim AR et al.

Quelle: Clinical and translational gastroenterology [Clin Transl Gastroenterol] 2025 Nov 01; Vol. 16 (11), pp. e00924. Date of Electronic Publication: 2025 Nov 01.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101532142 Publication Model: Electronic Cited Medium: Internet ISSN: 2155-384X (Electronic) Linking ISSN: 2155384X NLM ISO Abbreviation: Clin Transl Gastroenterol Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , Herpes Zoster Vaccine*/immunology , Herpes Zoster Vaccine*/administration & dosage , Herpes Zoster Vaccine*/adverse effects , Inflammatory Bowel Diseases*/drug therapy , Inflammatory Bowel Diseases*/immunology , Herpes Zoster*/prevention & control , Herpes Zoster*/immunology , Immunogenicity, Vaccine* , Tumor Necrosis Factor Inhibitors*/therapeutic use , Tumor Necrosis Factor Inhibitors*/adverse effects , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/adverse effects, Humans ; Female ; Male ; Prospective Studies ; Adult ; Middle Aged ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Vaccines, Synthetic/immunology ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/adverse effects ; Immunity, Cellular/drug effects ; Immunity, Humoral ; Herpesvirus 3, Human/immunology ; Treatment Outcome

Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study.

Autoren: da Costa Ferreira S Parra RS Sassaki LY et al.

Quelle: Gastroenterologia y hepatologia [Gastroenterol Hepatol] 2025 Nov; Vol. 48 (9), pp. 502396. Date of Electronic Publication: 2025 Feb 21.

Publikationsart: Journal Article; Observational Study; Multicenter Study; Comparative Study

Info zur Zeitschrift: Publisher: Elsevier España Country of Publication: Spain NLM ID: 8406671 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0210-5705 (Print) Linking ISSN: 02105705 NLM ISO Abbreviation: Gastroenterol Hepatol Subsets: MEDLINE

MeSH-Schlagworte: Colitis, Ulcerative*/drug therapy , Infliximab*/therapeutic use , Infliximab*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/adverse effects, Humans ; Male ; Female ; Retrospective Studies ; Adult ; Middle Aged ; Treatment Outcome ; Remission Induction

Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study.

Autoren: Tsai SY Ananthakrishnan AN Winter HS et al.

Quelle: Paediatric drugs [Paediatr Drugs] 2025 Nov; Vol. 27 (6), pp. 761-770. Date of Electronic Publication: 2025 Oct 08.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: Springer International Country of Publication: Switzerland NLM ID: 100883685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2019 (Electronic) Linking ISSN: 11745878 NLM ISO Abbreviation: Paediatr Drugs Subsets: MEDLINE

MeSH-Schlagworte: Venous Thromboembolism*/chemically induced , Venous Thromboembolism*/epidemiology , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Inflammatory Bowel Diseases*/drug therapy , Gastrointestinal Agents*/adverse effects , Gastrointestinal Agents*/therapeutic use , Colitis, Ulcerative*/drug therapy , Crohn Disease*/drug therapy , Biological Products*/adverse effects , Biological Products*/therapeutic use, Humans ; Male ; Female ; Child ; Adolescent ; Ustekinumab/adverse effects ; Ustekinumab/therapeutic use ; Child, Preschool ; Risk Factors

Real-world efficacy of ustekinumab and vedolizumab in pediatric and young adult patients with inflammatory bowel disease.

Autoren: Hsu D Lee J Kotzen A et al.

Quelle: Journal of pediatric gastroenterology and nutrition [J Pediatr Gastroenterol Nutr] 2025 Nov; Vol. 81 (5), pp. 1197-1207. Date of Electronic Publication: 2025 Aug 20.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley Country of Publication: United States NLM ID: 8211545 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-4801 (Electronic) Linking ISSN: 02772116 NLM ISO Abbreviation: J Pediatr Gastroenterol Nutr Subsets: MEDLINE

MeSH-Schlagworte: Ustekinumab*/therapeutic use , Ustekinumab*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/adverse effects , Inflammatory Bowel Diseases*/drug therapy , Colitis, Ulcerative*/drug therapy, Humans ; Retrospective Studies ; Male ; Female ; Child ; Adolescent ; Treatment Outcome ; Young Adult ; Crohn Disease/drug therapy ; Off-Label Use ; Remission Induction

Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab.

Autoren: Granot M Nachum N Krauthammer A et al.

Quelle: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2025 Nov; Vol. 57 (11), pp. 2128-2134. Date of Electronic Publication: 2025 Sep 08.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 100958385 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3562 (Electronic) Linking ISSN: 15908658 NLM ISO Abbreviation: Dig Liver Dis Subsets: MEDLINE

MeSH-Schlagworte: Infliximab*/immunology , Infliximab*/therapeutic use , Infliximab*/administration & dosage , Adalimumab*/therapeutic use , Adalimumab*/immunology , Adalimumab*/administration & dosage , Drug Substitution* , Crohn Disease*/drug therapy , Crohn Disease*/immunology , Gastrointestinal Agents*/immunology , Gastrointestinal Agents*/therapeutic use , Colitis, Ulcerative*/drug therapy , Colitis, Ulcerative*/immunology , Inflammatory Bowel Diseases*/drug therapy , Inflammatory Bowel Diseases*/immunology, Humans ; Female ; Male ; Retrospective Studies ; Child ; Adolescent ; Treatment Outcome ; Antibodies/blood

Effectiveness and safety of third-line advanced therapies in patients with ulcerative colitis: A multicentre retrospective cohort study: Third-line treatment in UC.

Autoren: Bertrand A Meyer A Kirchgesner J et al.

Quelle: Clinics and research in hepatology and gastroenterology [Clin Res Hepatol Gastroenterol] 2025 Nov; Vol. 49 (9), pp. 102699. Date of Electronic Publication: 2025 Sep 29.

Publikationsart: Journal Article; Multicenter Study; Observational Study

Info zur Zeitschrift: Publisher: Elsevier Masson Country of Publication: France NLM ID: 101553659 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2210-741X (Electronic) Linking ISSN: 22107401 NLM ISO Abbreviation: Clin Res Hepatol Gastroenterol Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Colitis, Ulcerative*/drug therapy , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/adverse effects , Piperidines*/therapeutic use , Piperidines*/adverse effects , Pyrimidines*/therapeutic use , Pyrimidines*/adverse effects , Pyrrolidines*/therapeutic use , Pyrrolidines*/adverse effects , Ustekinumab*/therapeutic use , Ustekinumab*/adverse effects, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome

Current Landscape of Novel Therapeutic Agents and Drug Targets in Irritable Bowel Syndrome.

Autoren: Joshi DC Raina N Joshi N et al.

Quelle: Archiv der Pharmazie [Arch Pharm (Weinheim)] 2025 Nov; Vol. 358 (11), pp. e70133.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Wiley-VCH Verlag GmbH & Co. KGaA Country of Publication: Germany NLM ID: 0330167 Publication Model: Print Cited Medium: Internet ISSN: 1521-4184 (Electronic) Linking ISSN: 03656233 NLM ISO Abbreviation: Arch Pharm (Weinheim) Subsets: MEDLINE

MeSH-Schlagworte: Irritable Bowel Syndrome*/drug therapy , Irritable Bowel Syndrome*/physiopathology , Gastrointestinal Agents*/pharmacology , Gastrointestinal Agents*/therapeutic use, Humans ; Animals

Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation.

Autoren: Chin S Con D Hilley P et al.

Quelle: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2025 Nov; Vol. 62 (10), pp. 1003-1011. Date of Electronic Publication: 2025 Jul 15.

Publikationsart: Journal Article; Multicenter Study

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE

MeSH-Schlagworte: Liver Transplantation* , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Inflammatory Bowel Diseases*/drug therapy , Biological Products*/therapeutic use , Biological Products*/adverse effects , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/adverse effects, Humans ; Female ; Male ; Retrospective Studies ; Middle Aged ; Adult ; Immunosuppressive Agents/therapeutic use ; Immunosuppressive Agents/adverse effects ; Ustekinumab/therapeutic use ; Ustekinumab/adverse effects

Efficacy and safety of Mirikizumab in the treatment of moderate to severe inflammatory bowel diseases: a systematic review and updated meta-analysis.

Autoren: Mekontso JGK Bena Nnang JY Fodop SGJ et al.

Quelle: Inflammopharmacology [Inflammopharmacology] 2025 Oct; Vol. 33 (10), pp. 5895-5907. Date of Electronic Publication: 2025 Sep 29.

Publikationsart: Journal Article; Systematic Review; Meta-Analysis; Review

Info zur Zeitschrift: Publisher: Birkhäuser Country of Publication: Switzerland NLM ID: 9112626 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1568-5608 (Electronic) Linking ISSN: 09254692 NLM ISO Abbreviation: Inflammopharmacology Subsets: MEDLINE

MeSH-Schlagworte: Inflammatory Bowel Diseases*/drug therapy , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal*/adverse effects , Antibodies, Monoclonal*/therapeutic use , Gastrointestinal Agents*/adverse effects , Gastrointestinal Agents*/therapeutic use, Humans ; Randomized Controlled Trials as Topic/methods ; Treatment Outcome ; Severity of Illness Index ; Remission Induction/methods

Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies.

Autoren: Schreiber S Colombel JF Hanauer SB et al.

Quelle: Inflammatory bowel diseases [Inflamm Bowel Dis] 2025 Oct 01; Vol. 31 (10), pp. 2714-2724.

Publikationsart: Journal Article; Randomized Controlled Trial; Comparative Study

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: England NLM ID: 9508162 Publication Model: Print Cited Medium: Internet ISSN: 1536-4844 (Electronic) Linking ISSN: 10780998 NLM ISO Abbreviation: Inflamm Bowel Dis Subsets: MEDLINE

MeSH-Schlagworte: Infliximab*/administration & dosage , Infliximab*/therapeutic use , Colitis, Ulcerative*/drug therapy , Crohn Disease*/drug therapy , Immunosuppressive Agents*/therapeutic use , Immunosuppressive Agents*/administration & dosage , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/therapeutic use , Gastrointestinal Agents*/administration & dosage , Gastrointestinal Agents*/therapeutic use , Gastrointestinal Agents*/pharmacokinetics, Humans ; Female ; Male ; Adult ; Injections, Subcutaneous ; Middle Aged ; Treatment Outcome ; Drug Therapy, Combination